By Michael Dabaie

 

Precigen Inc. shares were up 12% to $2.55 in premarket trade Monday after the U.S. Food and Drug Administration granted fast track designation for PRGN-3006 UltraCAR-T in acute myeloid leukemia.

The company said it was granted the designation for PRGN-3006 UltraCAR-T in patients with relapsed or refractory AML. Precigen said AML is among the most common types of leukemia in adults. AML is a cancer that starts in the bone marrow, but most often moves into the blood.

FDA previously granted PRGN-3006 orphan drug designation.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

April 04, 2022 08:43 ET (12:43 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Precigen (NASDAQ:PGEN)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Precigen Charts.
Precigen (NASDAQ:PGEN)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Precigen Charts.